서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 181 to 240 of 242

Issue DateTitle / Author(s) / CitationFileAltmetrics
2019-01
The risk of herpes zoster in patients with non-small cell lung cancer according to chemotherapy regimens: Tyrosine kinase inhibitors versus cytotoxic chemotherapy

Choi, Ji Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Jo, Seong Jin

Cancer Research and Treatment, Vol.51 No.1, pp.169-177

view fileDOI
2019-01
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
DOI
2019-02
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
DOI
2019-02
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
DOI
2019-02
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis
DOI
2019-05
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC
DOI
2019-05
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
DOI
2019-06
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
DOI
2019-06
NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors
DOI
2019-07
Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer

Choi, Mihong; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog

Clinical Lung Cancer, Vol.20 No.4, pp.E442-E451

DOI
2019-07
Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib

Kim, Seulki; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Alm, Yong-Oon; Keam, Bhumsuk; Heo, Dae Seog

Cancer Research and Treatment, Vol.51 No.3, pp.951-962

view fileDOI
2019-07
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
view fileDOI
2019-07
Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer
view fileDOI
2019-07
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
DOI
2019-07
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
DOI
2019-08
Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study
DOI
2019-09
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Ock, Chan-Young; Yoo, Shin-Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong Wan; Chung, Doo Hyun; Heo, Dae Seog

The Korean Journal of Internal Medicine, Vol.34 No.5, pp.1116-1124

view fileDOI
2019-09
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial
DOI
2019-09
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis
DOI
2019-09
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog

Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566

DOI
2019-10
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
DOI
2019-10
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
DOI
2019-10
The impact of social media on citation rates in coloproctology

Jeong, J. W.; Kim, M. J.; Oh, H. -K; Jeong, S.; Kim, M. H.; Cho, J. R.; Kim, D. -W; Kang, S. -B

Colorectal Disease, Vol.21 No.10, pp.1175-1182

DOI
2019-11
Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies
view fileDOI
2019-11
Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?
view fileDOI
2019-11
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
view fileDOI
2019-12
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
DOI
2020
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma
view fileDOI
2020-01
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
DOI
2020-01
Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial
DOI
2020-01
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
DOI
2020-02
Risk stratification of symptomatic brain metastases by clinical and FDG PET parameters for selective use of prophylactic cranial irradiation in patients with extensive disease of small cell lung cancer
DOI
2020-02
Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study
DOI
2020-03
Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis
DOI
2020-03
Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
DOI
2020-03
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
DOI
2020-03
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
DOI
2020-04
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
DOI
2020-05
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study
DOI
2020-06
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
DOI
2020-08
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
DOI
2020-09
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC
DOI
2020-10
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
DOI
2020-11
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
DOI
2020-11
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
DOI
2020-11
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
DOI
2020-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
DOI
2021-01
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients withEGFRmutation-positive locally advanced/metastatic non-small-cell lung cancer
DOI
2021-01
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
DOI
2021-02
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
DOI
2021-02
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
DOI
2021-02
A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer
DOI
2021-03
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
DOI
2021-06
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues
DOI
2021-06
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
DOI
2021-07
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
DOI
2021-07
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
DOI
2021-08
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium

Shimizu, Toshio; Kim, Dong-Wan; Loong, Herbert H.; Lin, Chia-Chi; Ng, Matthew C. H.; Yamamoto, Noboru; Ma, Brigette; Tan, Daniel S. W.

Asia-Pacific Journal of Clinical Oncology, Vol.17 No.4, pp.388-395

DOI
2021-08
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer
DOI
2021-09
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
DOI
1 2 3 4 5